SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (9514)1/30/2003 1:56:34 PM
From: Icebrg  Read Replies (1) of 9719
 
Rick

>>Yeah, the "one alfa4-beta7 epitope is the same as another" argument is a weak one, and that weakness was also seductive for me>>

So you are suggesting that MLN02 might bind to the wrong place on the alfa4-beta7 or not strongly enough and therefore not be effective. That is of course a possibility. I think I have seen a similar argumentation is the case of EGF receptor antagonists. If that is indeed the case, the outlook for the UC trial should also be rather bad.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News